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Antimicrobial synergy between carprofen
and doxycycline against methicillin-
resistant Staphylococcus pseudintermedius
ST71
Rikke Prejh Brochmann1†, Alexandra Helmfrid1†, Bimal Jana1, Zofia Magnowska1 and Luca Guardabassi1,2*
Abstract
Background: New therapeutic strategies are needed to face the rapid spread of multidrug-resistant staphylococci
in veterinary medicine. The objective of this study was to identify synergies between antimicrobial and non-antimicrobial
drugs commonly used in companion animals as a possible strategy to restore antimicrobial susceptibility in
methicillin-resistant Staphylococcus pseudintermedius (MRSP).
Results: A total of 216 antimicrobial/non-antimicrobial drug combinations were screened by disk diffusion using
a clinical MRSP sequence type (ST) 71 strain resistant to all six antimicrobials tested (ampicillin, ciprofloxacin,
clindamycin, doxycycline, oxacillin and trimethoprim/sulfamethoxazole). The most promising drug combination
(doxycycline-carprofen) was further assessed by checkerboard testing extended to four additional MRSP strains
belonging to ST71 or ST68, and by growth inhibition experiments.
Seven non-antimicrobial drugs (bromhexine, acepromazine, amitriptyline, clomipramine, carprofen, fluoxetine and
ketoconazole) displayed minimum inhibitory concentrations (MICs) ranging between 32 and >4096 mg/L, and
enhanced antimicrobial activity of one or more antimicrobials. Secondary screening by checkerboard assay
revealed a synergistic antimicrobial effect between carprofen and doxycycline, with the sum of the fractional
inhibitory concentration indexes (ΣFICI) ranging between 0.3 and 0.5 depending on drug concentration. Checkerboard
testing of multiple MRSP strains revealed a clear association between synergy and carriage of tetK, which is a typical
feature of MRSP ST71. An increased growth inhibition was observed when MRSP ST71 cells in exponential phase were
exposed to 0.5/32 mg/L of doxycycline/carprofen compared to individual drug exposure.
Conclusions: Carprofen restores in vitro susceptibility to doxycycline in S. pseudintermedius strains carrying tetK such as
MRSP ST71. Further research is warranted to elucidate the molecular mechanism behind the identified synergy and its
linkage to tetK.
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Background
Occurrence of methicillin-resistant staphylococci in
animals is a reason for concern in relation to both
public and animal health [1]. In small animal veterinary
medicine, infections caused by methicillin-resistant
Staphylococcus pseudintermedius (MRSP) pose a major
therapeutic challenge since some MRSP strains, such as
the European epidemic clone sequence type (ST) 71, are
virtually resistant to all systemic antimicrobial prod-
ucts licensed for use in dogs [2]. As it is unlikely that
new antimicrobial classes active against MRSP will
enter the veterinary drug market in the near future,
new therapeutic strategies are needed to exploit the
current antimicrobial arsenal. Combination therapy is
one of the possible strategies that can be used to
manage severe MRSP infections that cannot be cured
by topical antiseptic treatment. Some antimicrobial
combinations such as amoxicillin clavulanate and po-
tentiated sulphonamides are widely used in human
and veterinary medicine. Research is warranted to
identify new combinations of drugs acting on differ-
ent targets concurrently. It has been hypothesized
that combination antimicrobial therapy may prevent
or delay development of resistance [3]. Promising re-
sults have been shown by combining antimicrobials
with small non-antimicrobial helper molecules inter-
fering with resistance [4].
Pharmaceutical preparations targeting eukaryotic
cells and used for management of non-infectious dis-
eases, hereafter defined as non-antimicrobial drugs,
represent an unexplored source to potentiate existing
antimicrobials, restore susceptibility against resistant
strains or allow new uses and indications. Various
non-antimicrobial drugs have shown in vitro anti-
microbial activity [5] but their potential use in com-
bination with existing antimicrobial drugs has never
been tested systematically on veterinary pathogens.
The objective of this study was to identify synergies
between antimicrobial and non-antimicrobial drugs
commonly used in small animal veterinary medicine
as a possible strategy to restore antimicrobial suscep-
tibility in MRSP. This objective was achieved by i) a
double disk diffusion primary screening of six anti-
microbial and 36 non-antimicrobial drugs, ii) minimum
inhibitory concentration (MIC) testing of selected non-
antimicrobials displaying antimicrobial activity and inter-
action with one or more antimicrobial disk in the primary
screening, and iii) checkerboard secondary screening to
assess synergy of the selected antimicrobial/non-anti-
microbial combinations using a model strain of MRSP
ST71 resistant to all antimicrobials tested. The most
promising combination was further investigated by growth
inhibition analysis and checkerboard testing of additional
MRSP strains.
Methods
Selection of antimicrobials and non-antimicrobials
Six antimicrobials were selected to represent the five
antimicrobial classes most commonly used in dogs and
cats: β-lactams [ampicillin (AMP) and oxacillin (OXA)],
fluoroquinolones [ciprofloxacin CIP)], lincosamides
[clindamycin (CLI)], tetracyclines [doxycycline (DOX)]
and potentiated sulfonamides [trimethoprim/sulfameth-
oxazole (SXT)] [6]. Although amoxicillin is the most
frequently used penicillin in clinical practice, AMP
was used as a surrogate as recommended by Clinical
Laboratory Standard Institute (CLSI) [7]. Similarly,
OXA was used for testing methicillin resistance ac-
cording to CLSI guidelines [7]. Although CIP is not
licensed for veterinary use, this fluoroquinolone was
used instead of enrofloxacin, which largely metabo-
lized to ciprofloxacin under in vivo conditions [8].
Thirty-six non-antimicrobials used in small animal
practice were selected based on data on veterinary usage
of drugs in Denmark (VetStat) [9], recommendations on
frequency of usage by veterinary professionals at the
local university hospital, and availability of the active
compounds. Table 1 lists clinical use, solvent and sup-
plier for each non-antimicrobial used in the study.
Bacteria strains and media
MRSP ST71 strain E104 resistant to all six antimicro-
bials tested was used for primary and secondary screen-
ing. Checkerboard testing was extended to four
additional MRSP strains including ST71 (E032 and
E095) and another widely distributed multidrug-resistant
MRSP clone, ST68 (E122 and E135). All strains were
grown on blood agar (Oxoid, United Kingdom) and in-
cubated overnight at 37 °C prior to testing. All tests were
performed using cation-adjusted Mueller-Hinton agar or
broth (Sigma-Aldrich, Germany) using S. aureus ATCC
29213 as quality control strain.
Double disk diffusion test (primary screening)
The strain inoculum was prepared and plated according
to CLSI guidelines for disk diffusion [7]. The following
disk concentrations were used: AMP (25 μg), CIP
(10 μg), CLI (10 μg), DOX (30 μg), OXA (5 μg) and SXT
(1.25/25 μg). One antimicrobial disk was tested for each
plate. The antimicrobial disk was placed at the centre of
the plate and disks impregnated with 20 μL of non-
antimicrobial solution at standard concentration (2 g/L)
were applied at a 5 mm of distance from the antimicro-
bial disk. An antimicrobial disk not surrounded by non-
antimicrobial disks was used as control on the same
plate. Following overnight incubation at 37 °C, the plates
were read to detect interactions between antimicrobial
and non-antimicrobial disks. A clear extension of the
edge of the inhibition zone of the antimicrobial disk in
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proximity of the non-antimicrobial disk was interpreted
as a positive result.
MIC determination by broth microdilution
The MICs of seven non-antimicrobials displaying inter-
action with antimicrobial disks in the primary screening
were determined by broth microdilution [7]. The follow-
ing stock concentrations were prepared: bromhexine
[8192 mg/L, 75 % dimethyl sulfoxide (DMSO)]; clomip-
ramine, acepromaxine and ketoconazole (1024 mg/L,
20 % DMSO); carprofen (1024 mg/L, 1.6 % DMSO);
amitriptyline and fluoxetine (1024 mg/L). Serial two-fold
dilutions were prepared in 96-well round-bottom micro-
titer plates (Thermo Scientific). The range of concentra-
tions tested was determined individually for each
compound and ranged between 0.5 and 4096 mg/L.
Table 1 List of non-antimicrobial drugs selected for this study
Non-antimicrobial drug Clinical use Solvent Supplier
Prednisolone sodium phosphate Immunosuppressant Water Maymó
Cyclosporine DMSO Sigma-Aldrich
Dexamethasone sodium phosphate Water Alfasan
Praziquantel Anthelmintic DMSO Haupt Pharma
Ondansetrona Gastrointestinal problems DMSO Sigma-Aldrich
Omeprazole DMSO Sigma-Aldrich
Ranitidinea Water Sigma-Aldrich
Metoclopramidea Water Dechra
Salbutamol/Albuterol Respiratory problems Water Sigma-Aldrich
Fluticasonea DMSO Sigma-Aldrich
Theophyllinea Water Sigma-Aldrich
Sildenafila DMSO Sigma-Aldrich
Bromhexinea DMSO Zoopan
Carprofen Pain and inflammation DMSO Chanelle
Meloxicam DMSO Dopharma
Phenylbutazonea DMSO Alfasan
Paracetamol/Acetaminophena Water SP Veterinaria
Estriol Urinary problems DMSO Haupt Pharma
Medroxy-progesterone actetate Hormonal problems DMSO Alfasan
Levothyroxine DMSO Dechra
Thiamazol/Methiamazol Water Dechra
Trilostane DMSO Dechra
Osaterone DMSO Virbac
Methylergometrine/Methylergonovinea Water Sigma-Aldrich
Levetiracetama Epilepsy Water No data
Pimobendan Heart failure DMSO Dechra
Digoxina DMSO Kela
Atenolola Water Kela
Captoprila Water Novartis
Furosemide Diuretics DMSO Alfasan
Spironolactone DMSO Haupt Pharma
Clomipramine Psychological effects Water Haupt Pharma
Acepromaxine Water Alfasan
Amitriptylinea Water Haupt Pharma
Fluoxetine hydrochloridea Water Sigma-Aldrich
Ketoconazolea Antifungals DMSO Sigma-Aldrich
aOnly registered for human use in Denmark
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Checkerboard assay (secondary screening)
Two-dimensional checkerboard assays [10] were used
to assess synergy for seven antimicrobial/non-antimicro-
bial combinations selected by the primary screening. Car-
profen was additionally tested with tetracycline (TET) to
check if the synergy effect was antimicrobial class-specific.
Fractional Inhibitory Concentration Indexes (FICI) were
calculated for each combination to determine whether the
effect was truly synergistic (ΣFICI ≤ 0.5), no interaction
(ΣFICI >0.5–4) or antagonistic (ΣFICI >4.0) depending on
drug concentration [11]. The highest concentration of
antimicrobials and non-antimicrobials used for the
checkerboard assays was twice the MIC. The highest
concentration possible was used if non-antimicrobials
could not be dissolved at the desired concentration.
Two-fold dilutions were prepared and inoculated with
the test strain according to the CLSI guidelines for
broth microdilution [7]. After overnight incubation at
37 °C, plates were shaken at 1200 rpm for 1 min in a
Bioshake XP (Quantifoil Instruments GmbH). The
optical density of growth cultures was measured at
600 nm (OD600) using a Powerwave XS (BioTek)
operated by software Gen5. Percentages of growth
inhibition were calculated for each well using the
following equation:
% inhibition ¼ 100− Mean OD of treated culture
Mean OD of untreated culture
 
 100
Growth inhibition assay
The inhibitory effect of carprofen/DOX was evaluated
by exposing the model strain in exponential growth
phase to the two drugs alone and in combination.
Drug concentrations approximating the peak serum
concentration (Cmax) achieved in dogs by standard
dosage in single drug therapy were used for this
assay. According to the scientific literature, the Cmax
of DOX is 2.74–6.32 mg/L upon oral administration
of 5–10 mg/Kg [12], whereas the Cmax of carprofen is
32.6–38 mg/L upon treatment with 4.0 mg/Kg [13].
Taking into consideration DOX pharmacokinetic (PK)
data in dogs and pharmacodynamic (PD) properties
against S. pseudintermedius, [12] the strain was exposed
to 0.5 mg/L DOX and 16, 32 or 64 mg/L carprofen.
Briefly, overnight culture of the strain was diluted to 0.05
at an optical density of 600 nm (OD600), grown up to
OD600 0.4 (10
8 cell forming units (CFU)/mL) and diluted
again 1:1000 (105 CFU/mL). For the next 12 h, samples
were collected every hour to perform standard bacterial
counts. At OD600 0.1 (10
7 CFU/mL, approx. after 3.5 h)
aliquots of the culture were transferred into small flasks.
Individual cultures were exposed to the selected con-
centrations of each drug alone or in combination and
further incubated with untreated control. All cultures
were setup in triplicates and incubated in water baths
at 37 °C with shaking at 180 rpm. The percentage of
growth inhibition at a specific time point was calcu-
lated using the following equation:
% inhibition ¼ 100− Mean CFU of treated culture
Mean CFU of untreated culture
 
 100:
Results
Seven of the 36 non-antimicrobial drugs tested in the
primary screening were shown to enlarge the edge of the
inhibition zone of at least one antimicrobial disk: ace-
promazine (CLI, OXA), amitriptyline (AMP, OXA),
bromexine (OXA), clomipramine (OXA), carprofen
(AMP, DOX), fluoxetine (CIP, SXT) and ketoconazole
(OXA, SXT). Ketoconazole displayed the highest anti-
bacterial activity (MIC = 32 mg/L), followed by aceproma-
zine, clomipramine and fluoxetine (MIC = 64 mg/L),
amitriptyline and carprofen (MIC = 256 mg/L) and brom-
hexine (MIC > 4096 mg/L).
These seven non-antimicrobials were further tested
by checkerboard assays in combination with the anti-
microbial displaying the largest inhibition zone in the
double disk diffusion assay. The ΣFICI of bromhexine
was not determined because the drug could not be
dissolved at a sufficient concentration to determine
the MIC (MIC > 4096 mg/L). Carprofen displayed syn-
ergistic antimicrobial activity with DOX, whereas the
other five antimicrobial/non-antimicrobial combina-
tions showed no interaction (ΣFICI = 1.01–1.35).
Additional checkerboard assays were performed to
determine at which drug concentrations carprofen
displayed synergy with DOX or TET. Synergy was
observed in presence of 64 mg/L of carprofen and
0.25–1 mg/L DOX (ΣFICI = 0.31–0.5). At lower car-
profen concentration (32 mg/L), synergy was only dis-
played in presence of 1 mg/L of DOX (ΣFICI index =
0.38), whereas at higher concentration (128 mg/L) no
effect was observed in presence of 0.125–1 mg/L of
DOX (ΣFICI = 0.53–0.75). No effect was observed by
increasing the concentration of DOX up to 2 mg/L
with carprofen concentrations ranging from 16 to
64 mg/L (ΣFICI = 0.56–0.75). The synergy patterns of
carprofen and TET were similar to those observed for
DOX, even though they were less pronounced and re-
quired higher antibiotic concentrations (8–16 mg/L),
resulting in a ΣFICI between 0.38 and 0.5 (Fig. 1).
Checkerboard testing of four additional MRSP strains
(two ST71 and two ST68) revealed synergy for the
two ST71 strains when DOX and carprofen were
combined at concentrations of 0.5/64, 1/64, 2/64 or
2/32 mg/L. On the contrary, no synergy was observed
for the two ST68 strains (Fig. 1). At DOX/carprofen
concentrations achievable in dogs by single drug
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therapy (0.5/32 mg/L), the percentage of growth in-
hibition measured by spectrophotometry was 54 %
higher for the three ST71 than for the two ST68
strains.
Growth inhibition experiments were performed to as-
sess the effect of carprofen and DOX, individually and in
combination, during exponential growth of the model
strain MRSP E104. Based on viable cell counts, the effect
Fig. 1 Heat plots of the antibacterial effects of DOX or TET in combination with carprofen on three methicillin-resistant Staphylococcus
pseudintermedius ST71 strains (E104, E032 and E095) and two ST68 strains (E122 and E135). The level of growth inhibition is expressed by
colour intensity: the more intense the colour is, the less inhibited the strain was. The Fractional Inhibitory Concentration Index (FICI) was
calculated for wells with no visible growth (white colour). Indexes of ΣFICI ≤ 0.5 correspond to synergistic effect, ΣFICI >0.5–4 no effect,
ΣFICI > 4 antagonistic. The heat plots show the average of three biological replicates
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of DOX and carprofen alone were significantly lower
than for the combination of the two drugs (Fig. 2). After
4.5 h of exposure to 0.5 mg/L of DOX, the growth of
strain was inhibited by 8.3 %; exposure to 16, 32 or
64 mg/L of carprofen alone resulted in 6.2, 26.6 and
40.9 % growth inhibition, respectively; exposure to
0.5 mg/L of DOX in combination with 16, 32 or 64 mg/L
of carprofen inhibited growth by 45.7, 89.5 and 100 %, re-
spectively, indicating a clear synergistic effect on growth
inhibition by the drug combination.
Discussion
This study indicates that approximately 19 % of the 36
non-antimicrobial drugs tested were able to potentiate
the antibacterial activity of one or more known antimi-
crobials against MRSP. All the seven non-antimicrobials
that were found to have antimicrobial-potentiating activ-
ity (acepromazine, amitriptyline, bromexine, carprofen,
clomipramine, fluoxetine and ketoconazole) have been
previously reported to possess antibacterial activity
[14–20]. Carprofen was shown to be particularly in-
teresting to potentiate the antimicrobial activity of
DOX as it displayed synergy at drug concentrations
that may be achieved during therapy in dogs. Carprofen is
a non-steroidal anti-inflammatory drug (NSAID) for
veterinary treatment of inflammation and pain man-
agement. It has earlier been reported to have a clin-
ical effect when used in combination with tilmicosin
for antimicrobial therapy of bovine respiratory disease
[21]. DOX is the most widely used tetracycline in
small animal practice due to low systemic toxicity
[22] and higher antimicrobial activity compared to
TET [12]. However, due to widespread tetracycline re-
sistance, DOX is presently regarded as a second
choice antibiotic for most indications except upper
respiratory tract infections [23].
The synergy between carprofen and DOX was studied
in multiple MRSP strains, leading to the identification of
a b
c
Fig. 2 Growth inhibition of methicillin-resistant Staphylococcus pseudintermedius E104 exposed to doxycycline (0.5 mg/L DOX, filled squares),
carprofen (CPF, filled triangle pointing upwards) and the combination of the two drugs (DOX + CPF, filled triangle pointing downwards) using
three concentrations of CPF (a: 64 mg/L; b: 32 mg/L; c: 16 mg/L). The control (filled circles) was treated with neither DOX nor CPF. Error bars
denote standard deviation (SD) of three biological replicates
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an association between the synergistic effect of this drug
combination and strains belonging to the clonal lineage
ST71, which harbours the efflux pump-mediated tetra-
cycline resistance gene tetK [2]. In contrast, no synergy
was observed for MRSP strains belonging to ST68,
which are consistently associated with tetM, [2] an unre-
lated tetracycline resistance gene encoding ribosomal
protection of the drug target. The association between
tetK and DOX/carprofen synergy was further illustrated
by the analysis of strain cultures exposed to concentra-
tions of DOX/carprofen achievable in dogs by single
therapy (0.5/32 mg/L), which showed a significantly
higher growth inhibition in the three strains harbouring
tetK compared to the two strains containing tetM. These
results suggest that DOX/carprofen synergy only occurs
in strains carrying tetK. The molecular mechanism
behind the identified synergy and its linkage to tetK
remains unknown. Such synergy mechanism is un-
likely linked to the bactericidal effect of carprofen on
DNA replication, suggesting that carprofen interacts
with multiple targets in the bacterial cell. Various
mechanisms are possible, including inhibition of tetK
gene expression, blockage of the TetK efflux pump or
interference with the energy source used by TetK to
pump DOX out of the cell.
The recommended dosage for oral administration of
carprofen in dogs is 4 mg/Kg of body weight daily. This
dosage leads to peak plasma concentration of 35.30 ±
2.70 mg/L at 1.25 ± 0.25 h [13]. Higher dosages up to
9 mg/Kg were shown to be well tolerated in healthy bea-
gles [13]. These data suggest that the carprofen (32 mg/L)
concentration required for synergy with DOX (0.5 mg/L)
can be achieved in vivo. However, there may be marked
differences between in vitro and in vivo conditions due to
serum protein binding, which affects drug’s efficiency.
Further PD/PK studies are needed to assess the thera-
peutic potential of DOX/carprofen, including in vitro
experiments assessing the effects of canine serum protein
binding on carprofen activity. In an earlier study by
Brentnall et al. [24] the influence of oxytetracycline on
carprofen PD and PK was evaluated for therapy of bacter-
ial pneumonia in calves, indicating that no alteration to
carprofen dosage is required when the two drugs are co-
administered. There is an obvious rationale for investigat-
ing the use of NSAIDs in combination to DOX for some
canine infections, such as upper respiratory tract infec-
tions. Carprofen analogues able to establish synergy with
DOX at lower concentrations could be developed to facili-
tate translation of the results of this study into veterinary
clinical practice. Furthermore, since MRSP is a common
cause of skin and soft tissue infections, carprofen/DOX
formulations could be developed for topical use, which
may allow achievement of higher carprofen concentra-
tions at the infection site. Interestingly, DOX has earlier
been reported to have anti-inflammatory effects [25].
Thus, the combination of the two drugs might also
have enhanced anti-inflammatory activity compared to
single therapy.
The interactions between non-antimicrobial drugs
and tetracyclines have occasionally been explored for
potential clinical applications in human medicine.
One example is the recent study by Ejim et al. [26]
describing the synergistic effect of minocycline in
combination with loperamide, a medication used for
control of diarrhoea. Our study is the first attempt to
investigate this alternative avenue for possible veterin-
ary clinical applications.
Conclusion
The results show that carprofen is a potential antimicro-
bial helper drug to restore susceptibility to DOX in
DOX-resistant MRSP strains carrying tetK. This finding
is of clinical relevance since the epidemic multidrug-
resistant clone MRSP ST71 is virtually resistant to all
antimicrobial drugs licensed for veterinary use and has
been previously shown to carry consistently tetK as the
only tetracycline resistance determinant. More research
is needed in order to understand the mode of action of
this drug combination as well as to assess the clinical
potential of carprofen as a DOX helper drug in small
animal medicine.
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